Are We Nearing the End of the Debate Regarding Steroid Efficacy and Safety in IgAN?
Released On
February 24, 2023
Expires On
February 24, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Nephrologists, Internists, PCPs, Dialysis Staff, Medical Directors, Pharmacists, Aligned HCPs
Topic(s)
Kidney Disease, Progressive Kidney Disease, Berger Disease, Immunoglobulin‐A Nephropathy, IgAN, Kidney Failure, Dialysis, Kidney Transplantation, Proteinuria, RAS inhibition, KDIGO, KDIGO guidelines, Budesonide, Delayed‐release Budesonide, Sparsentan, Dapagliflozin, Bortezomib, Chronic Kidney Disease, CKD, End Stage Kidney Disease, ESKD, End Stage Renal Disease, ESRD
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.
In collaboration with Kidney Disease: Improving Global Outcomes (KDIGO).
This activity is supported by an educational grant from Calliditas.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The educational design of this activity addresses the needs of nephrologists, internists, PCPs, dialysis staff and medical directors, pharmacists, and aligned HCPs.
Statement of Need/Program Overview
If left untreated, immunoglobulin‐A nephropathy (IgAN) can lead to kidney failure, dialysis, and transplantation. The current standard of care, RAS inhibition, has limited efficacy, while recently updated KDIGO guidelines for the management of IgAN highlight the risks associated with systemic corticosteroids and immunosuppressants. An enhanced understanding of the underlying pathophysiology of IgAN could lead to improved options in reducing the first step in the inflammatory process.
Join a panel of expert nephrologists to review the changing standards of care for IgAN and explore the mechanisms of action, safety, and efficacy of new therapeutic options. Panelists will discuss the key roles of Peyer’s patches in the inflammatory process in glomerular mesangium, which can be reduced with delayed‐release budesonide. The activity will also review new and emerging surrogate endpoints for kidney-disease clinical trials and help clinicians understand how to utilize trials to evaluate patient response to therapy.
Educational Objectives
After completing this activity, the participant should be better able to:
- Identify the manifestations and diagnostic process for IgAN
- Recognize patients who are at high risk of progression despite RAS inhibition
- Explain the role of the ileal lymphoid tissue, specifically Peyer’s patches as a major source of IgA responsible for IgAN, and describe the implications for treatment with steroids
- Summarize the safety and efficacy data of the delayed-release budesonide formulation in proteinuria reduction and kidney function
Faculty
Jürgen Floege, MD
Professor of Medicine
Division of Nephrology and
Rheumatology
RWTH Aachen University Hospital
Germany
Jai Radhakrishnan, MD, MS
Professor of Medicine, Columbia
University Medical Center
Clinical Director, Division of Nephrology
Columbia University Vagelos College of
Physicians and Surgeons
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
|---|---|
Jürgen Floege, MD | Consulting Fee (e.g., Advisory Board): |
Jai Radhakrishnan, MD, MS | Consulting Fee (e.g., Advisory Board): |
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
Instructions for Participation and Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Physician Accreditation Support:
For information about the physician accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.